

Highlights of This Issue 1973

SPECIAL FEATURES

CCR 20th Anniversary Commentary

- 1975** CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel—How Far Science Has Come
Sami I. Bashour and Nuhad K. Ibrahim


CCR Translations

- 1978** PLEKHA5: A Key to Unlock the Blood–Brain Barrier?
Sylvia C. Eisele, Corey M. Gill, Ganesh M. Shankar, and Priscilla K. Brastianos
See related article, p. 2138
- 1981** The Yin and Yang of Alloreactivity: Chronic Graft-versus-Host Disease and Leukemia Relapse
Saar Gill
See related article, p. 2020

CCR New Strategies

- 1984** New Strategies in Glioblastoma: Exploiting the New Biology
Howard A. Fine

Molecular Pathways

- 1989** Molecular Pathways: Targeting *NRG1* Fusions in Lung Cancer
Lynnette Fernandez-Cuesta and Roman K. Thomas
- 1995** Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy
 Efficacy via Reduction in Oxygen Demand
Alexander Lin and Amit Maity

Reviews

- 2001** Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?
Bruno Paiva, Noemi Puig, Ramón García-Sanz, and Jesús F. San Miguel on behalf of the Grupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study groups

- 2009** Genomic Landscape of Human Papillomavirus–Associated Cancers
Maria Rusan, Yvonne Y. Li, and Peter S. Hammerman


CANCER THERAPY: CLINICAL

- 2020** Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
Michael Boyiadzis, Mukta Arora, John P. Klein, Anna Hassebroek, Michael Hemmer, Alvaro Urbano-Ispizua, Joseph H. Antin, Brian J. Bolwell, Jean-Yves Y. Cahn, Mitchell S. Cairo, Corey S. Cutler, Mary E. Flowers, Robert P. Gale, Roger Herzig, Luis M. Isola, David A. Jacobsohn, Madan H. Jagasia, Thomas R. Klumpp, Stephanie J. Lee, Effie W. Petersdorf, Stella Santarone, Stephen R. Spellman, Harry C. Schouten, Leo F. Verdonck, John R. Wingard, Daniel J. Weisdorf, Mary M. Horowitz, and Steven Z. Pavletic
See related commentary, p. 1981


PERSONALIZED MEDICINE AND IMAGING

- 2029** Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
Lorraine A. Chantrill, Adnan M. Nagrial, Clare Watson, Amber L. Johns, Mona Martyn-Smith, Skye Simpson, Scott Mead, Marc D. Jones, Jaswinder S. Samra, Anthony J. Gill, Nicole Watson, Venessa T. Chin, Jeremy L. Humphris, Angela Chou, Belinda Brown, Adrienne Morey, Marina Pajic, Sean M. Grimmond, David K. Chang, David Thomas, Lucille Sebastian, Katrin Sjoquist, Sonia Yip, Nick Pavlakis, Ray Asghari, Sandra Harvey, Peter Grimison, John Simes, and Andrew V. Biankin, on behalf of the Australian Pancreatic Cancer Genome Initiative (APGI) and the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (AGITG)
- 2038** Polymorphisms in *MIR27A* Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy
Ursula Amstutz, Steven M. Offer, Johanna Sistonen, Markus Joerger, Robert B. Diasio, and Carlo R. Largiadèr
- 2045** Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia
Brian Parkin, Peter Ouillette, Mehmet Yildiz, Kamlai Saiya-Cork, Kerby Shedden, and Sami N. Malek

Table of Contents

- 2057** **MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial**
Michael Weller, Ghazaleh Tabatabai, Bärbel Kästner, Jörg Felsberg, Joachim P. Steinbach, Antje Wick, Oliver Schnell, Peter Hau, Ulrich Herrlinger, Michael C. Sabel, Hans-Georg Wirsching, Ralf Ketter, Oliver Bähr, Michael Platten, Jörg C. Tonn, Uwe Schlegel, Christine Marosi, Roland Goldbrunner, Roger Stupp, Krisztian Homicsko, Josef Pichler, Guido Ninkhah, Jürgen Meixensberger, Peter Vajkoczy, Spyros Kollias, Johannes Hüsing, Guido Reifenberger, and Wolfgang Wick for the DIRECTOR Study Group
- 2065** **PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance**
 Howard M. Stern, Humphrey Gardner, Tomasz Burzykowski, Wafaa Elatre, Carol O'Brien, Mark R. Lackner, Gary A. Pestano, Angela Santiago, Ivonne Villalobos, Wolfgang Eiermann, Tadeusz Pienkowski, Miguel Martin, Nicholas Robert, John Crown, Paolo Nuciforo, Valerie Bee, John Mackey, Dennis J. Slamon, and Michael F. Press
- 2107** **Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation—An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302**
Jasdeep K. Saggarr and Ian F. Tannock
- 2115** **Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors**
Sutapa Sinha, Justin Boysen, Michael Nelson, Charla Secreto, Steven L. Warner, David J. Bearss, Connie Lesnick, Tait D. Shanafelt, Neil E. Kay, and Asish K. Ghosh
- 2127** **Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer**
Vianey Gonzalez-Villasana, Enrique Fuentes-Mattei, Cristina Ivan, Heather J. Dalton, Cristian Rodriguez-Aguayo, Ricardo J. Fernandez-de Thomas, Burcu Aslan, Paloma del C. Monroig, Guermarie Velazquez-Torres, Rebecca A. Previs, Sunila Pradeep, Nermin Kahraman, Huamin Wang, Pinar Kanlikilicer, Bulent Ozpolat, George Calin, Anil K. Sood, and Gabriel Lopez-Berestein

CANCER THERAPY: PRECLINICAL

- 2075** **CD47 Enhances *In Vivo* Functionality of Artificial Antigen-Presenting Cells**
Heiko Bruns, Catherine Bessell, Juan Carlos Varela, Carl Haupt, Jerry Fang, Shirin Pasemann, Andreas Mackensen, Mathias Oelke, Jonathan P. Schneck, and Christian Schütz
- 2084** **Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency**
 Wan-Ching Yen, Marcus M. Fischer, Fumiko Axelrod, Christopher Bond, Jennifer Cain, Belinda Cancilla, William R. Henner, Rene Meisner, Aaron Sato, Jalpa Shah, Tracy Tang, Breanna Wallace, Min Wang, Chun Zhang, Ann M. Kapoun, John Lewicki, Austin Gurney, and Timothy Hoey
- 2096** **Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma**
Salvia Jain, Xavier Jirau-Serrano, Kelly M. Zullo, Luigi Scotto, Carmine F. Palermo, Stephen A. Sastra, Kenneth P. Olive, Serge Cremers, Tiffany Thomas, Ying Wei, Yuan Zhang, Govind Bhagat, Jennifer E. Amengual, Changchun Deng, Charles Karan, Ronald Realubit, Susan E. Bates, and Owen A. O'Connor

BIOLOGY OF HUMAN TUMORS

- 2138** **PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis**
Lucia B. Jilaveanu, Fabio Parisi, Meaghan L. Barr, Christopher R. Zito, William Cruz-Munoz, Robert S. Kerbel, David L. Rimm, Marcus W. Bosenberg, Ruth Halaban, Yuval Kluger, and Harriet M. Kluger
See related commentary, p. 1978
- 2148** **The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence *In Situ* Hybridization in Multiple Myeloma**
Gang An, Zengjun Li, Yu-Tzu Tai, Chirag Acharya, Qian Li, Xiaoqi Qin, Shuhua Yi, Yan Xu, Xiaoyan Feng, Chengwen Li, Jiawei Zhao, Lihui Shi, Meirong Zang, Shuhui Deng, Weiwei Sui, Mu Hao, Dehui Zou, Yaozhong Zhao, Junyuan Qi, Tao Cheng, Kun Ru, Jianxiang Wang, Kenneth C. Anderson, and Luguai Qiu
- 2157** **Emergence of Multiple *EGFR* Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer**
Sabrina Arena, Beatriz Bellosillo, Giulia Siravegna, Alejandro Martínez, Israel Cañadas, Luca Lazzari, Noelia Ferruz, Mariangela Russo, Sandra Misale, Iria González, Mar Iglesias, Elena Gavilan, Giorgio Corti, Sebastijan Hobor, Giovanni Crisafulli, Marta Salido, Juan Sánchez, Alba Dalmases, Joaquim Bellmunt, Gianni De Fabritiis, Ana Rovira, Federica Di Nicolantonio, Joan Albanell, Alberto Bardelli, and Clara Montagut

Table of Contents

2167 IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma

Craig C. Carson, Stergios J. Moschos, Sharon N. Edmiston, David B. Darr, Nana Nikolaishvili-Feinberg, Pamela A. Groben, Xin Zhou, Pei Fen Kuan, Shaily Pandey, Keefe T. Chan, Jamie L. Jordan, Honglin Hao, Jill S. Frank, Dennis A. Hopkinson, David C. Gibbs, Virginia D. Alldredge, Eloise Parrish, Sara C. Hanna, Paula Berkowitz, David S. Rubenstein, C. Ryan Miller, James E. Bear, David W. Ollila, Norman E. Sharpless, Kathleen Conway, and Nancy E. Thomas

2177 Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach

Pleun Hombrink, Chopie Hassan, Michel G.D. Kester, Lorenz Jahn, Margot J. Pont, Arnoud H. de Ru, Cornelis A.M. van Bergen, Marieke Griffioen, J.H. Frederik Falkenburg, Peter A. van Veelen, and Mirjam H.M. Heemskerk

LETTERS TO THE EDITOR

2187 RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Letter

Steven Sorscher

2188 RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Response

Rona Yaeger and Leonard B. Saltz

RETRACTION

2189 Retraction: Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression

CORRECTIONS

2190 Correction: Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer

2192 Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors


 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows establishment of blood brain barrier (BBB) tight junctions. Immunofluorescence staining demonstrates ZO-1 expression within the top endothelial layer of an *in vitro* BBB. For details, see the article by Jilaveanu and colleagues on page 2138 of this issue.



Clinical Cancer Research

21 (9)

Clin Cancer Res 2015;21:1973-2192.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/21/9>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/21/9>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.